IGF-1 release is stimulated by growth hormone secretion from the anterior pituitary gland, and this study sought to assess the feasibility of increasing IGF-1 levels through recombinant human growth hormone (rhGH) treatment, in addition to establishing safety and exploring efficacy of rhGH in children with PMS.<h4>Methods</h4>rhGH was administered once daily for 12 weeks to six children with PMS using an open-label design. The gene discussed is IGF1; the disease is premenstrual tension.